Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership
Rhea-AI Filing Summary
Passage Bio, Inc. received an amended Schedule 13G/A from Vestal Point Capital, LP and Ryan Wilder regarding its common stock. The filing states that the Reporting Persons now have 0 shares beneficially owned and 0% of the outstanding common stock, with no sole or shared voting or dispositive power reported.
The Reporting Persons describe Vestal Point Capital, LP as investment adviser to a fund and managed account that previously held Passage Bio common stock, and clarify that the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 0%
Shares beneficially owned: 0.00 shares
Sole voting power: 0.00 shares
+1 more
4 metrics
Beneficial ownership
0%
Percent of Passage Bio common stock class reported by each Reporting Person
Shares beneficially owned
0.00 shares
Row 9 of the cover page for each Reporting Person
Sole voting power
0.00 shares
Row 5 of the cover page for each Reporting Person
Shared voting power
0.00 shares
Row 6 of the cover page for each Reporting Person
Key Terms
beneficial owner, Investment Manager, Ownership of 5 percent or less of a class, dispositive power
4 terms
beneficial owner regulatory
"not be construed as an admission that any Reporting Person is, for the purposes of Section 13, the beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Investment Manager financial
"Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser"
Ownership of 5 percent or less of a class regulatory
"Item 5. | Ownership of 5 Percent or Less of a Class. | Ownership of 5 percent or less of a class"
dispositive power regulatory
"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 0.00"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
FAQ
What does the Vestal Point Capital Schedule 13G/A filing mean for Passage BIO (PASG)?
Vestal Point Capital, LP and Ryan Wilder report 0 shares and 0% beneficial ownership of Passage Bio common stock. They also report no sole or shared voting or dispositive power over PASG shares.
How much of Passage BIO (PASG) stock does Vestal Point Capital currently own?
According to the amended Schedule 13G/A, Vestal Point Capital and Ryan Wilder report beneficial ownership of 0 shares of Passage Bio common stock, representing 0% of the class outstanding.
Who are the reporting persons in this Passage BIO (PASG) Schedule 13G/A?
The reporting persons are Vestal Point Capital, LP, a Delaware limited partnership and investment adviser, and Ryan Wilder, its Chief Investment Officer and Managing Partner, who reports with respect to the same Passage Bio common stock accounts.
What is the significance of the 'Ownership of 5 percent or less of a class' statement for PASG?
The filing specifies that the Reporting Persons have ownership of 5 percent or less of Passage Bio’s common stock, quantified as 0%. This indicates they are no longer a 5% beneficial owner under Section 13 rules.
Where are Passage BIO (PASG) and Vestal Point Capital based according to the filing?
Passage Bio’s principal executive offices are at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247. Vestal Point Capital and Ryan Wilder list their business office at 632 Broadway, Suite 602, New York, NY 10012.
AI-generated analysis. How Rhea-AI works. Not financial advice.